An Evaluation of 2015-2019 United States Respiratory Syncytial Virus Hospitalizations as a Framework to Develop Potential Strategies for the Prevention of the Hospital Burden Among Infants
- Robert Suss; Eric Simões
Access Resources
About
This article evaluates RSV hospitalizations in the U.S. from 2015 to 2019 to develop strategies for reducing hospital burdens among infants. It describes two prevention methods: nirsevimab, a monoclonal antibody, and the RSVpreF maternal vaccine. The study uses data from children's hospitals to compare these strategies based on birth timing relative to the RSV season. Findings suggest that both methods can prevent many hospitalizations but vary in effectiveness depending on when infants are born during the season. The study emphasizes tailoring immunization strategies based on regional RSV patterns for better cost-effectiveness and protection outcomes.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.